There is a difference between building awareness and building understanding, and the recent trajectory of ibogaine is the story of what happens when the first outruns the second.
For years, ibogaine lived at the edges of medicine. Most people had never heard of it. The few who had were the Bwiti themselves, or the practitioners, clinicians, researchers, and addiction specialists who circled the compound, along with the people desperate enough to look past the conventional treatment system and willing to travel to a clinic or a tribe to do it. The substance occupied a strange and contradictory place: obscure, controversial, hard to reach, and yet quietly producing outcomes that demanded investigation. What it did not have was attention.
Then the attention arrived.
The modern psychedelic renaissance brought cameras, podcasts, conferences, documentaries, venture capital, ballot measures, and a steady stream of personal testimony. One by one, people walked out of powerful experiences convinced they had found the answer to suffering itself. Many of them meant well, and some almost certainly saved lives. But somewhere along the way the conversation began to move faster than the evidence beneath it.
Here the field made an error that deserves precision, because it can be misread in two directions at once. The first error was overreach: ibogaine became a substance that could supposedly treat everything. Addiction. PTSD. Depression. Traumatic brain injury. Anxiety. Moral injury. Chronic despair. Spiritual disconnection. The list lengthened with every interview, every stage, every headline, growing in roughly the manner of any claim repeated more often than it is tested.
The opposite error, less discussed but equally distorting, is to shrink ibogaine down to a single indication and call that humility. It is not. Ibogaine is genuinely unusual in its pharmacological breadth. It acts, along with its long-lived metabolite noribogaine, across an unusually wide set of targets, and that breadth is precisely why the compound is so interesting to study and so difficult to reduce to one mechanism. The honest position is therefore narrower than the enthusiasts and wider than the skeptics: the experience is broad, but the evidence for any given application is not uniform across that breadth.
Where the human data is strongest, it is strongest by a wide margin. The most compelling clinical promise remains opioid use disorder and severe substance dependence, where the existing human data, though limited, is genuinely striking, and where conventional treatment fails so often that the bar for "worth investigating" is easily cleared. What distinguishes ibogaine in that setting is not a vague mood benefit but two specific and unusual signals: a marked attenuation of opioid withdrawal and craving, and a set of motor and neurological effects that have drawn separate scientific interest in their own right. Past these, the ground gets softer: intriguing signals, early data, plausible hypotheses, open questions. Enough to justify serious science. Not nearly enough to support the claims that have entered public conversation.
It is also worth saying plainly what the enthusiasm tends to skip, because the omission is itself part of the pattern. The intensity of the ibogaine experience is not a feature to be celebrated. It is a cost to be managed. The compound carries real cardiac risk, has measurable hepatic and neurological burden, and has killed people who took it without screening. Whether a less punishing experience, a lower dose, a different route, or a structural analog could deliver the same anti-addiction and neurological benefits with less physiological danger is one of the most important open questions in the field. It is a hypothesis worth pursuing, not a result already in hand, and the difference between those two things is the whole subject of this essay.
Science accumulates. It moves at the speed of replication, of failed studies repeated until something holds. Enthusiasm has no such governor, and when the two fall out of step the gap between them does not stay empty. It fills with belief.
This is not an argument that advocacy should never have happened. It is an argument that the advocacy should have been disciplined. It should have moved first through the people equipped to carry it: researchers, clinicians, the traditional stakeholders who have held this knowledge for generations, conservation experts, and regulators. It should have happened in working groups and study protocols before it happened on stages.
Instead, much of the public conversation was carried by people who had recently undergone the experience, were still standing inside its emotional afterglow, and happened to possess the money, charisma, or media access to amplify their own testimony. Personal transformation is real, and many of these stories gave hope to people who badly needed it. But a profound experience does not, by itself, qualify anyone to shape policy, describe mechanisms, speak for indigenous traditions, forecast public-health outcomes, or decide how a scarce botanical resource should enter modern medicine. That was the error the field kept making. It treated the intensity of an experience as if it conferred authority over the experience's meaning.
An entire ecosystem grew up around that mistake. Conferences, foundations, fundraisers, gala dinners, and organizations all assembled themselves around the promise of accelerating progress, and many of them were sincere about it. Some did real work. But attention had become its own kind of currency, and currency draws the people who know how to accumulate it. The incentives inverted without notice. It is easier to raise awareness than to produce evidence, easier to host an event than to fund a study that might take years to read out, easier to assemble a compelling narrative than the data it claims to rest on. A field that needed scientists kept producing advocates instead, and advocacy, unlike understanding, can be manufactured on a deadline.
